Fully Covered Stent-TIPS for Advanced HCC Patients with Portal Vein Tumor Thrombus-Related Severe Symptomatic Portal Hypertension.

IF 4.2 3区医学 Q2 ONCOLOGY

Journal of Hepatocellular Carcinoma Pub Date : 2025-01-14 eCollection Date: 2025-01-01 DOI:10.2147/JHC.S491153

Zechuan Liu, Tianshi Lyu, Jinming Yang, Yong Xie, Siyuan Fan, Li Song, Yinghua Zou, Jian Wang

{"title":"Fully Covered Stent-TIPS for Advanced HCC Patients with Portal Vein Tumor Thrombus-Related Severe Symptomatic Portal Hypertension.","authors":"Zechuan Liu, Tianshi Lyu, Jinming Yang, Yong Xie, Siyuan Fan, Li Song, Yinghua Zou, Jian Wang","doi":"10.2147/JHC.S491153","DOIUrl":null,"url":null,"abstract":"Purpose: Portal vein tumor thrombus (PVTT)-related severe symptomatic portal hypertension (SPH) leads to a poor prognosis in patients with advanced hepatocellular carcinoma (HCC). Traditional transjugular intrahepatic portosystemic shunt (TIPS) using covered plus bare stent can effectively relieve SPH, however, the bare segment is susceptible to obstruction due to PVTT invasion. This study aimed to evaluate the safety and efficacy of fully covered stent-TIPS (FCS-TIPS) for treatment of PVTT-related SPH in advanced HCC patients.Patients and methods: This retrospective study enrolled 25 patients with advanced HCC who underwent FCS-TIPS for PVTT-related severe SPH from June 2018 to January 2024. The evaluated outcomes included overall survival (OS), technical success rate, reduction in portal venous pressure gradient (PPG), stent patency rate, SPH control rate, liver function and complications.Results: The technical success rate was 100% without perioperative deaths or severe procedure-related adverse events. The average PPG decreased by 13.4±4.6 mmHg. The overall symptom control rate of SPH was 96.0%. Variceal bleeding, ascites/hydrothorax, and enteropathy control rates were 100%, 95.0%, and 100%, respectively. Liver function showed mild improvement one month after TIPS. One patient (4.0%) experienced overt hepatic encephalopathy (OHE) and three (12.0%) patients developed shunt dysfunction during the follow-up period. None of the patients experienced shunt-induced extrahepatic metastasis. The median OS was 6.0 months and the cumulative survival rates at 3, 6, 12 months were 80.0%, 52.0% and 21.3%.Conclusion: FCS-TIPS is safe and effective for treating PVTT-related severe SPH and can serve as a bridging therapy for advanced HCC.","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"29-41"},"PeriodicalIF":4.2000,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742244/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatocellular Carcinoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JHC.S491153","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Portal vein tumor thrombus (PVTT)-related severe symptomatic portal hypertension (SPH) leads to a poor prognosis in patients with advanced hepatocellular carcinoma (HCC). Traditional transjugular intrahepatic portosystemic shunt (TIPS) using covered plus bare stent can effectively relieve SPH, however, the bare segment is susceptible to obstruction due to PVTT invasion. This study aimed to evaluate the safety and efficacy of fully covered stent-TIPS (FCS-TIPS) for treatment of PVTT-related SPH in advanced HCC patients.

Patients and methods: This retrospective study enrolled 25 patients with advanced HCC who underwent FCS-TIPS for PVTT-related severe SPH from June 2018 to January 2024. The evaluated outcomes included overall survival (OS), technical success rate, reduction in portal venous pressure gradient (PPG), stent patency rate, SPH control rate, liver function and complications.

Results: The technical success rate was 100% without perioperative deaths or severe procedure-related adverse events. The average PPG decreased by 13.4±4.6 mmHg. The overall symptom control rate of SPH was 96.0%. Variceal bleeding, ascites/hydrothorax, and enteropathy control rates were 100%, 95.0%, and 100%, respectively. Liver function showed mild improvement one month after TIPS. One patient (4.0%) experienced overt hepatic encephalopathy (OHE) and three (12.0%) patients developed shunt dysfunction during the follow-up period. None of the patients experienced shunt-induced extrahepatic metastasis. The median OS was 6.0 months and the cumulative survival rates at 3, 6, 12 months were 80.0%, 52.0% and 21.3%.

Conclusion: FCS-TIPS is safe and effective for treating PVTT-related severe SPH and can serve as a bridging therapy for advanced HCC.

查看原文本刊更多论文

晚期HCC伴门静脉肿瘤血栓相关严重症状性门静脉高压的全覆盖支架- tips治疗

目的：门静脉肿瘤血栓（PVTT）相关的严重症状性门静脉高压（SPH）导致晚期肝癌（HCC）患者预后不良。传统的经颈静脉肝内门体分流术（TIPS）采用覆盖+裸支架可有效缓解SPH，但裸段易因PVTT侵袭而梗阻。本研究旨在评价全覆盖支架- tips （FCS-TIPS）治疗晚期HCC患者pvtt相关SPH的安全性和有效性。患者和方法：本回顾性研究纳入了2018年6月至2024年1月期间接受FCS-TIPS治疗pvtt相关严重SPH的25例晚期HCC患者。评估结果包括总生存期（OS）、技术成功率、门静脉压梯度（PPG）降低、支架通畅率、SPH控制率、肝功能和并发症。结果：技术成功率为100%，无围手术期死亡和严重的手术相关不良事件。平均PPG下降13.4±4.6 mmHg。SPH总体症状控制率为96.0%。静脉曲张出血、腹水/胸水和肠病控制率分别为100%、95.0%和100%。肝功能在TIPS治疗后1个月有轻度改善。随访期间1例（4.0%）出现显性肝性脑病（OHE）， 3例（12.0%）出现分流功能障碍。所有患者均未发生分流引起的肝外转移。中位OS为6.0个月，3、6、12个月的累计生存率分别为80.0%、52.0%和21.3%。结论：FCS-TIPS治疗pvtt相关性重度SPH安全有效，可作为晚期HCC的桥接治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊